|
1
|
Buckner JC: Factors influencing survival
in high-grade gliomas. Semin Oncol. 30:10–14. 2003. View Article : Google Scholar
|
|
2
|
Curran WJ Jr, Scott CB, Horton J, Nelson
JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO,
Krisch RE, et al: Recursive partitioning analysis of prognostic
factors in three Radiation Therapy Oncology Group malignant glioma
trials. J Natl Cancer Inst. 85:704–710. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
DeAngelis LM: Brain tumors. N Eng J Med.
344:114–123. 2001. View Article : Google Scholar
|
|
4
|
Ohgaki H and Kleihues P: Epidemiology and
etiology of gliomas. Acta Neuropathol. 109:93–108. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem
cells promote radioresistance by preferential activation of the DNA
damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bao S, Wu Q, Sathornsumetee S, Hao Y, Li
Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD and Rich JN: Stem
cell-like glioma cells promote tumor angiogenesis through vascular
endothelial growth factor. Cancer Res. 66:7843–7848. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zeppernick F, Ahmadi R, Campos B, Dictus
C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B and
Herold-Mende CC: Stem cell marker CD133 affects clinical outcome in
glioma patients. Clin Cancer Res. 14:123–129. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shi Y, Seto E, Chang LS and Shenk T:
Transcriptional repression by YY1, a human GLI-Krüippel-related
protein, and relief of repression by adenovirus E1A protein. Cell.
67:377–388. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Park K and Atchison ML: Isolation of a
candidate repressor/activator, NF-E1 (YY-1, delta), that binds to
the immunoglobulin kappa 3′enhancer and the immunoglobulin
heavy-chain mu E1 site. Proc Natl Acad Sci USA. 88:9804–9808. 1991.
View Article : Google Scholar
|
|
10
|
Hariharan N, Kelley DE and Perry RP:
Delta, a transcription factor that binds to downstream elements in
several polymerase II promoters, is a functionally versatile zinc
finger protein. Proc Natl Acad Sci USA. 88:9799–9803. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Flanagan JR, Becker KG, Ennist DL, Gleason
SL, Driggers PH, Levi BZ, Appella E and Ozato K: Cloning of a
negative transcription factor that binds to the upstream conserved
region of Moloney murine leukemia virus. Mol Cell Biol. 12:38–44.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thomas MJ and Seto E: Unlocking the
mechanisms of transcription factor YY1: Are chromatin modifying
enzymes the key? Gene. 236:197–208. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shi Y, Lee JS and Galvin KM: Everything
you have ever wanted to know about Yin Yang 1…. Biochim Biophys
Acta. 1332:F49–F66. 1997.PubMed/NCBI
|
|
14
|
Iuchi S and Kuldell N: Zinc Finger
Proteins: From Atomic Contact to Cellular Function. Springer
Science Business Media; New York, NY: 2007
|
|
15
|
Gordon S, Akopyan G, Garban H and Bonavida
B: Transcription factor YY1: Structure, function, and therapeutic
implications in cancer biology. Oncogene. 25:1125–1142. 2006.
View Article : Google Scholar
|
|
16
|
Wilkinson FH, Park K and Atchison ML:
Polycomb recruitment to DNA in vivo by the YY1 REPO domain. Proc
Natl Acad Sci USA. 103:19296–19301. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thomassen M, Tan Q and Kruse TA: Gene
expression meta-analysis identifies metastatic pathways and
transcription factors in breast cancer. BMC Cancer. 8:3942008.
View Article : Google Scholar
|
|
18
|
Wan M, Huang W, Kute TE, Miller LD, Zhang
Q, Hatcher H, Wang J, Stovall DB, Russell GB, Cao PD, et al: Yin
Yang 1 plays an essential role in breast cancer and negatively
regulates p27. Am J Pathol. 180:2120–2133. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chinnappan D, Xiao D, Ratnasari A, Andry
C, King TC and Weber HC: Transcription factor YY1 expression in
human gastrointestinal cancer cells. Int J Oncol. 34:1417–1423.
2009.PubMed/NCBI
|
|
20
|
Kang W, Tong J, Chan A, Zhao J, Dong Y,
Wang S, Yang W, Sin FM, Ng SS, Yu J, et al: Yin Yang 1 contributes
to gastric carcinogenesis and its nuclear expression correlates
with shorter survival in patients with early stage gastric
adenocarcinoma. J Transl Med. 12:802014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Seligson D, Horvath S, Huerta-Yepez S,
Hanna S, Garban H, Roberts A, Shi T, Liu X, Chia D, Goodglick L and
Bonavida B: Expression of transcription factor Yin Yang 1 in
prostate cancer. Int J Oncol. 27:131–141. 2005.PubMed/NCBI
|
|
22
|
Sarkar FH, Li Y, Wang Z, Kong D and Ali S:
Implication of microRNAs in drug resistance for designing novel
cancer therapy. Drug Resist Updat. 13:57–66. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gal H, Pandi G, Kanner AA, Ram Z,
Lithwick-Yanai G, Amariglio N, Rechavi G and Givol D: MIR-451 and
Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells.
Biochem Biophys Res Commun. 376:86–90. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ruan T, He X, Yu J and Hang Z:
MicroRNA-186 targets Yes-associated protein 1 to inhibit Hippo
signaling and tumorigenesis in hepatocellular carcinoma. Oncol
Lett. 11:2941–2945. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun KX, Jiao JW, Chen S, Liu BL and Zhao
Y: MicroRNA-186 induces sensitivity of ovarian cancer cells to
paclitaxel and cisplatin by targeting ABCB1. J Ovarian Res.
8:802015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang TJ, Wang YX, Yang DQ, Yao DM, Yang
L, Zhou JD, Deng ZQ, Wen XM, Guo H, Ma JC, et al: Down-regulation
of miR-186 correlates with poor survival in de novo acute myeloid
leukemia. Clin Lab. 62:113–120. 2015.
|
|
27
|
Wang F, Jiang H, Wang S and Chen B: Dual
functional MicroRNA-186-5p targets both FGF2 and RelA to suppress
tumorigenesis of glioblastoma multiforme. Cell Mol Neurobiol.
37:1433–1442. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Allen M, Bjerke M, Edlund H, Nelander S
and Westermark B: Origin of the U87MG glioma cell line: Good news
and bad news. Sci Transl Med. 8:354re32016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sun L, Yao Y, Liu B, Lin Z, Lin L, Yang M,
Zhang W, Chen W, Pan C, Liu Q, et al: miR-200b and miR-15b regulate
chemotherapy-induced epithelial-mesenchymal transition in human
tongue cancer cells by targeting BMI1. Oncogene. 31:432–445. 2012.
View Article : Google Scholar
|
|
30
|
Liao XH, Lu DL, Wang N, Liu LY, Wang Y, Li
YQ, Yan TB, Sun XG, Hu P and Zhang TC: Estrogen receptor α mediates
proliferation of breast cancer MCF-7 cells via a
p21/PCNA/E2F1-dependent pathway. FEBS J. 281:927–942. 2014.
View Article : Google Scholar
|
|
31
|
Xiang Y, Lu DL, Li JP, Yu CX, Zheng DL,
Huang X, Wang ZY, Hu P, Liao XH and Zhang TC: Myocardin inhibits
estrogen receptor alpha-mediated proliferation of human breast
cancer MCF-7 cells via regulating MicroRNA expression. IUBMB Life.
68:477–487. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kataoka J, Shiraha H, Horiguchi S,
Sawahara H, Uchida D, Nagahara T, Iwamuro M, Morimoto H, Takeuchi
Y, Kuwaki K, et al: Loss of Runt-related transcription factor 3
induces resistance to 5-fluorouracil and cisplatin in
hepatocellular carcinoma. Oncol Rep. 35:2576–2582. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ali S, Ahmad A, Banerjee S, Padhye S,
Dominiak K, Schaffert JM, Wang Z, Philip PA and Sarkar FH:
Gemcitabine sensitivity can be induced in pancreatic cancer cells
through modulation of miR-200 and miR-21 expression by curcumin or
its analogue CDF. Cancer Res. 70:3606–3617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kong D, Li Y, Wang Z, Banerjee S, Ahmad A,
Kim HR and Sarkar FH: miR-200 regulates PDGF-D-mediated
epithelial-mesenchymal transition, adhesion, and invasion of
prostate cancer cells. Stem Cells. 27:1712–1721. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
36
|
Jia Y, Chen J, Zhu H, Jia ZH and Cui MH:
Aberrantly elevated redox sensing factor Nrf2 promotes cancer stem
cell survival via enhanced transcriptional regulation of ABCG2 and
Bcl-2/Bmi-1 genes. Oncol Rep. 34:2296–2304. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yu J, Ryan DG, Getsios S,
Oliveira-Fernandes M, Fatima A and Lavker RM: MicroRNA-184
antagonizes microRNA-205 to maintain SHIP2 levels in epithelia.
Proc Natl Acad Sci USA. 105:19300–19305. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Komatsu M, Sumizawa T, Mutoh M, Chen ZS,
Terada K, Furukawa T, Yang XL, Gao H, Miura N, Sugiyama T and
Akiyama S: Copper-transporting P-type adenosine triphosphatase
(ATP7B) is associated with cisplatin resistance. Cancer Res.
60:1312–1316. 2000.PubMed/NCBI
|
|
39
|
Kondo S, Barnett GH, Hara H, Morimura T
and Takeuchi J: MDM2 protein confers the resistance of a human
glioblastoma cell line to cisplatin-induced apoptosis. Oncogene.
10:2001–2006. 1995.PubMed/NCBI
|
|
40
|
Brescia P, Ortensi B, Fornasari L, Levi D,
Broggi G and Pelicci G: CD133 is essential for glioblastoma stem
cell maintenance. Stem Cells. 31:857–869. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lathia JD, Gallagher J, Heddleston JM,
Wang J, Eyler CE, Macswords J, Wu Q, Vasanji A, McLendon RE,
Hjelmeland AB and Rich JN: Integrin alpha 6 regulates glioblastoma
stem cells. Cell Stem Cell. 6:421–432. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sherry MM, Reeves A, Wu JK and Cochran BH:
STAT3 is required for proliferation and maintenance of multipotency
in glioblastoma stem cells. Stem Cells. 27:2383–2392. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
He W, Feng J, Zhang Y, Wang Y, Zang W and
Zhao G: MicroRNA-186 inhibits cell proliferation and induces
apoptosis in human esophageal squamous cell carcinoma by targeting
SKP2. Lab Invest. 96:317–324. 2016. View Article : Google Scholar
|
|
44
|
Brandes AA, Basso U, Reni M, Vastola F,
Tosoni A, Cavallo G, Scopece L, Ferreri AJ, Panucci MG, Monfardini
S, et al: First-line chemotherapy with cisplatin plus fractionated
temozolomide in recurrent glioblastoma multiforme: A phase II study
of the Gruppo Italiano Cooperativo di Neuro-Oncologia. J Clin
Oncol. 22:1598–1604. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Timmer-Bosscha H, Mulder NH and de Vries
E: Modulation of cis-diamminedichloroplatinum(II) resistance: A
review. Br J Cancer. 66:227–238. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen W, Yang Y, Chen B, Lu P, Zhan L, Yu
Q, Cao K and Li Q: miR-136 targets E2F1 to reverse cisplatin
chemosensitivity in glioma cells. J Neurooncol. 120:43–53. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang Q, Wang Z, Chu L, Li X, Kan P, Xin X,
Zhu Y and Yang P: The effects and molecular mechanisms of miR-106a
in multidrug resistance reversal in human glioma U87/DDP and U251/G
cell lines. PLoS One. 10:e01254732015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Eramo A, Ricci-Vitiani L, Zeuner A,
Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C and
De Maria R: Chemotherapy resistance of glioblastoma stem cells.
Cell Death Differ. 13:1238–1241. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Terada K, Schilsky ML, Miura N and
Sugiyama T: ATP7B (WND) protein. Int J Biochem Cell Biol.
30:1063–1067. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Bidlingmaier S, Zhu X and Liu B: The
utility and limitations of glycosylated human CD133 epitopes in
defining cancer stem cells. J Mol Med (Berl). 86:1025–1032. 2008.
View Article : Google Scholar
|
|
51
|
Uchida N, Buck DW, He D, Reitsma MJ, Masek
M, Phan TV, Tsukamoto AS, Gage FH and Weissman IL: Direct isolation
of human central nervous system stem cells. Proc Natl Acad Sci USA.
97:14720–14725. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang Y, Xing X, Zhan H, Li Q, Fan Y, Zhan
L, Yu Q and Chen J: EGFR inhibitor enhances cisplatin sensitivity
of human glioma cells. J Huazhong Univ Sci Technol Med Sci.
31:773–778. 2011. View Article : Google Scholar : PubMed/NCBI
|
